Literature DB >> 23813361

Intralesional antigen immunotherapy for the treatment of warts: current concepts and future prospects.

Ahmad Nofal1, Eman Salah, Eman Nofal, Ayman Yosef.   

Abstract

Many destructive and immunotherapeutic modalities have been used for the management of warts; however, an optimal treatment with high efficacy and absent or low recurrence has not been explored to date. Recently, the use of intralesional immunotherapy with different antigens has shown promising efficacy in the treatment of warts. We review the different aspects of this new modality, including candidates, types of warts treated, dosage, number and interval between treatment sessions, mode of action, efficacy, adverse effects, recurrence rate, advantages, disadvantages, current place and future prospects. A literature review revealed that healthy immune subjects are the best candidates, and a pre-sensitization test is usually done before the start of therapy. The dosage, the number and interval between sessions, and the success rates varied among the different studies. The mode of action is still uncertain, but is essentially mediated through stimulation of T helper-1 cell cytokine response. Adverse effects are mild and generally insignificant, and the recurrence rate is absent or low. Intralesional antigen immunotherapy seems to be a promising, effective and safe treatment modality for viral warts. Future well-designed and controlled studies would help to more clearly define its place in the challenging field of wart therapy.

Mesh:

Substances:

Year:  2013        PMID: 23813361     DOI: 10.1007/s40257-013-0018-8

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  5 in total

1.  The efficacy and safety of intralesional Candida vaccine versus topical diphencyproprobenone in immunotherapy of verruca vulgaris: A randomized comparative study.

Authors:  Mohamed H M El-Komy; Shahenda Gamal Shamma; Nermeen Ibrahim Bedair
Journal:  Arch Dermatol Res       Date:  2022-10-17       Impact factor: 3.033

2.  Complement component 3c and tumor necrosis factor-α systemic assessment after Candida antigen immunotherapy in cutaneous warts.

Authors:  Noha M Hammad; Amina A Abdelhadi; Manal M Fawzy; Ayman Marei
Journal:  Braz J Microbiol       Date:  2020-06-27       Impact factor: 2.476

3.  Psoriasis Exacerbation after Candida Antigen Immunotherapy Injection.

Authors:  Sameh Magdy Sarsik; Sarah Hamdy Soliman
Journal:  Skin Appendage Disord       Date:  2021-01-21

4.  Changes in Cytokine Profile with Immunotherapy in Viral Warts using Purified Protein Derivative, Mumps Measles Rubella Vaccine, and Mycobacterium w Vaccine.

Authors:  Amrita Sil; Sayantan Dasgupta; Somodyuti Chandra; Adrija Datta; Arini Banerjee; Nilay Kanti Das
Journal:  Indian J Dermatol       Date:  2021 Jan-Feb       Impact factor: 1.494

5.  Role of Intralesional Vitamin D3 in the Treatment of Cutaneous Warts.

Authors:  Insha Latif; Javeed Sultan; Aaqib Aslam; Iffat Hassan; Reeta Devi
Journal:  J Cutan Aesthet Surg       Date:  2021 Oct-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.